Antibody mix 2: CD4 FITC (BioLegend 357406), CD25 PE (BD555432), CD194
BV421 (BioLegend 395414), CD127 Alexa Flour 647 (BD558588), CD45 V500 (BD560779), CD45 RO PeCy7 (BD337168), CD3 PerCP Cy5.5, and HLA-DR APC H7/Cy7 (BD561358)
Global Markets Direct's, 'C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016', provides in depth analysis on C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted pipeline therapeutics.
The report provides comprehensive information on the C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
* The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4)
Anti-human monoclonal antibodies specific for apoptotic/inhibitory molecules (CD95 (Fas/Apo1), CD152 (CTLA-4), CD279 (PD1), CD274 (PD1-L), and CD357 (GITR)), activation molecules (CD25 (sIL2Ra), CD69, CD71, and HLA-DR), chemokine and homing receptors (CD194
(CCR4), CD197 (CCR7), and CD62L (L-selectin)), integrin (CD103 ([alpha]E[beta]7)), ectonucleotidase (CD39 (ENTPD1), CD73 (57NT)), naive (CD45RA), costimulatory molecules (CD40L (CD154), CD28, CD40, CD70, CD278(ICOS), and CD137 (4-1BB)), and immunoregulatory cytokines (IL10, TGF-[[beta].sub.1]) were used.